心力衰竭中的炎症:病理生理学和治疗策略
Jacinthe Boulet1, Vikas S Sridhar2, Nadia Bouabdallaoui1
1Department of Medicine, Division of Cardiology, Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada.
概括
炎症在心力衰竭 (HF) 的发展中起着复杂的作用. 了解免疫系统在HF表型和射出分数谱中的参与是新疗法的关键.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 病理生理学 病理生理学
背景情况:
- 几十年来,人们一直在研究炎症对心力衰竭 (HF) 的作用.
- 细胞因子和化学因子都与HF有关,但早期的治疗向产生了混合的结果,突出了途径的复杂性.
- 最近的研究表明,基于HF表型,不同的炎症作用是不同的.
研究的目的:
- 提供当代审查炎症在HF中的作用,通过先天性和适应性免疫调解.
- 为了检查高频的射出分数光谱内的炎症差异.
- 探索高频炎症中已确定的和新的炎症生物标志物.
主要方法:
- 关于炎症和HF的研究的文献综述.
- 对细胞因子和化学因子在HF病变发生过程中的参与进行分析.
- 检查免疫系统的作用 (先天性和适应性) 在HF.
- 对HF炎症的生物标志物的审查.
- 评估如何向炎症可能有利于现有和未来的HF疗法.
主要成果:
- 炎症与HF的发展和进展密切相关.
- 在不同的HF表型和射出分数水平上存在着不同的炎症作用.
- 炎症的生物标志物为HF病理生理学和进展提供了洞察力.
- 调节炎症通路显示出改善HF治疗结果的潜力.
结论:
- 由先天性和适应性免疫系统主导的炎症是心力衰竭的关键因素.
- 了解整个射出分数谱的HF炎症对于开发向疗法至关重要.
- 针对炎症的生物标志物和治疗策略有望促进心力衰竭管理.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
01:26Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:17Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K